摘要
肥胖是一个全球性问题,也是最常见的代谢紊乱,可导致许多相关疾病,如动脉高血压、缺血性心脏病、2型糖尿病、某些类型的癌症、脂质和尿酸代谢受损。在过去40年里,全球儿童和成人的肥胖患病率都在上升,这也是糖尿病患病率迅速上升的原因。目前,对产热组织,即棕色和米色脂肪组织的研究,从治疗肥胖症及其相关疾病的潜力来看,具有极大的价值。一种类似于胰高血糖素样肽-1 (GLP-1)的利拉鲁肽,用于治疗2型糖尿病,已被证明通过抑制食欲对减肥有积极的作用。然而,这并不是减肥的唯一机制。本文讨论了脂肪形成的主要分子和细胞机制,以及GLP-1及其类似物,特别是利拉鲁肽通过多种转录因子、信号通路和激素,包括褐色和米黄色脂肪组织,对这一过程的影响。同时,双肠促胰岛素对胰岛素抵抗和脂肪激活也有积极作用。大量研究的结果帮助我们更好地理解脂质代谢调节的外周机制,并证明了GLP-1类似物对糖尿病和肥胖的治疗效果。
关键词: 胰高血糖素样肽1型,肠促胰岛素,肥胖,胰岛素抵抗,2型糖尿病,胰高血糖素。
Current Molecular Medicine
Title:The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Volume: 21 Issue: 7
关键词: 胰高血糖素样肽1型,肠促胰岛素,肥胖,胰岛素抵抗,2型糖尿病,胰高血糖素。
摘要: Obesity is a global problem and the most common metabolic disorder leading to many associated diseases, such as arterial hypertension, ischemic heart disease, type 2 diabetes, certain types of cancer, impaired lipid and uric acid metabolism. The prevalence of obesity has risen globally in the past four decades in both children and adults, and it accounts for the rapid increase in the prevalence of diabetes. Currently, the study of thermogenic tissues, brown and beige adipose tissues, is of extreme value from the point of view of therapeutic potential for obesity and its associated diseases. An analogue of the glucagon-like peptide-1 (GLP-1) liraglutide, used in the treatment of type 2 diabetes, has been proven to have a positive effect on weight loss through appetite suppression. However, this mechanism of weight loss is not the only one involved. This article discusses the main molecular and cellular mechanisms of adipogenesis, as well as the effect of GLP-1 and its analogues, in particular liraglutide on this process through various transcription factors, signaling pathways, and hormones, including brown and beige adipose tissue. Also, the twincretins have had a positive effect on insulin resistance and fat beiging activation. The results of numerous studies have helped us to better understand the peripheral mechanisms of lipid metabolism regulation, and have demonstrated the effectiveness of GLP-1 analogues for the treatment of diabetes and obesity.
Export Options
About this article
Cite this article as:
The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?, Current Molecular Medicine 2021; 21 (7) . https://dx.doi.org/10.2174/1566524020666201201095029
DOI https://dx.doi.org/10.2174/1566524020666201201095029 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets Structural Chromosome Abnormalities Associated with Obesity: Report of Four New Subjects and Review of Literature
Current Genomics Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry